FDA Approves Solriamfetol Hydrochloride by Alkem Labs
The FDA has approved Solriamfetol Hydrochloride under application ANDA218722 submitted by Alkem Labs.
Published: June 23, 2026
Updated: June 23, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Wakefulness-promoting agent
Company: Alkem Labs
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Alkem Labs
Asset
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's approval of Solriamfetol Hydrochloride by Alkem Labs introduces a new competitor in the wakefulness-promoting agents market. This could shift market dynamics and necessitate strategic adjustments from existing players to maintain their competitive edge.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry strategies and sales performance of Solriamfetol Hydrochloride post-approval.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.